Patient characteristics according to immunohistochemically defined GC and non-GC phenotypes for rituximab and control group
| Characteristic . | Rituximab group . | Control group . | P, all . | ||||
|---|---|---|---|---|---|---|---|
| All . | GC . | Non-GC . | All . | GC . | Non-GC . | ||
| No. of patients (%) | 90 (100) | 50 (55.6) | 40 (44.4) | 104 (100) | 47 (45.2) | 57 (54.8) | .20 |
| Median age, y (range) | 60.9 (23-82) | 59.9 (27-77) | 62.3 (23-82) | 62.0 (25-83) | 60.0 (25-83) | 67.0 (29-80) | .64 |
| Age, no. (%) | |||||||
| Younger than 60 y | 40 (55.6) | 25 (50.0) | 15 (37.5) | 44 (42.3) | 22 (46.8) | 22 (38.6) | .77 |
| 60 y or older | 50 (44.4) | 25 (50.0) | 25 (62.5) | 60 (57.7) | 25 (53.2) | 35 (61.4) | |
| Sex, no. (%) | |||||||
| Male | 48 (53.3) | 21 (42.0) | 27 (67.5) | 59 (56.7) | 24 (51.1) | 35 (61.4) | .67 |
| Female | 42 (46.7) | 29 (58.0) | 13 (32.5) | 45 (43.3) | 23 (48.9) | 22 (38.6) | |
| Stage, no. (%) | |||||||
| I to II | 24 (26.7) | 15 (30.0) | 9 (22.5) | 33 (31.7) | 14 (29.8) | 19 (33.3) | .53 |
| III to IV | 66 (73.3) | 35 (70.0) | 31 (77.5) | 71 (68.3) | 33 (70.2) | 38 (66.7) | |
| IPI, no. (%) | |||||||
| 0 to 2 | 54 (60.0) | 32 (64.0) | 22 (55.0) | 65 (63.1) | 31 (66.0) | 34 (60.7) | .77 |
| 3 to 5 | 36 (40.0) | 18 (36.0) | 18 (45.0) | 38 (36.9) | 16 (34.0) | 22 (39.3) | |
| Missing | 0 | 0 | 0 | 1 | 0 | 1 | |
| Treatment, no. (%) | |||||||
| CHOP | 53 (58.9) | 29 (58.0) | 24 (60.0) | 60 (57.7) | 24 (51.1) | 36 (63.1) | .89 |
| Other | 37 (41.1) | 21 (42.0) | 16 (40.0) | 44 (42.3) | 23 (48.9) | 21 (36.9) | |
| Characteristic . | Rituximab group . | Control group . | P, all . | ||||
|---|---|---|---|---|---|---|---|
| All . | GC . | Non-GC . | All . | GC . | Non-GC . | ||
| No. of patients (%) | 90 (100) | 50 (55.6) | 40 (44.4) | 104 (100) | 47 (45.2) | 57 (54.8) | .20 |
| Median age, y (range) | 60.9 (23-82) | 59.9 (27-77) | 62.3 (23-82) | 62.0 (25-83) | 60.0 (25-83) | 67.0 (29-80) | .64 |
| Age, no. (%) | |||||||
| Younger than 60 y | 40 (55.6) | 25 (50.0) | 15 (37.5) | 44 (42.3) | 22 (46.8) | 22 (38.6) | .77 |
| 60 y or older | 50 (44.4) | 25 (50.0) | 25 (62.5) | 60 (57.7) | 25 (53.2) | 35 (61.4) | |
| Sex, no. (%) | |||||||
| Male | 48 (53.3) | 21 (42.0) | 27 (67.5) | 59 (56.7) | 24 (51.1) | 35 (61.4) | .67 |
| Female | 42 (46.7) | 29 (58.0) | 13 (32.5) | 45 (43.3) | 23 (48.9) | 22 (38.6) | |
| Stage, no. (%) | |||||||
| I to II | 24 (26.7) | 15 (30.0) | 9 (22.5) | 33 (31.7) | 14 (29.8) | 19 (33.3) | .53 |
| III to IV | 66 (73.3) | 35 (70.0) | 31 (77.5) | 71 (68.3) | 33 (70.2) | 38 (66.7) | |
| IPI, no. (%) | |||||||
| 0 to 2 | 54 (60.0) | 32 (64.0) | 22 (55.0) | 65 (63.1) | 31 (66.0) | 34 (60.7) | .77 |
| 3 to 5 | 36 (40.0) | 18 (36.0) | 18 (45.0) | 38 (36.9) | 16 (34.0) | 22 (39.3) | |
| Missing | 0 | 0 | 0 | 1 | 0 | 1 | |
| Treatment, no. (%) | |||||||
| CHOP | 53 (58.9) | 29 (58.0) | 24 (60.0) | 60 (57.7) | 24 (51.1) | 36 (63.1) | .89 |
| Other | 37 (41.1) | 21 (42.0) | 16 (40.0) | 44 (42.3) | 23 (48.9) | 21 (36.9) | |